Real-Time PCR Chemistries Key to Luminex's $34M EraGen Acquisition
June 23, 2011
Real-Time PCR Chemistries Key to Luminex's $34M EraGen Acquisition
Two years after Luminex and EraGen ended a licensing and distribution agreement that had coupled Luminex's bead-based detection system with EraGen's multiplex PCR chemistry, the companies will reunite through Luminex's planned $34 million acquisition of Eragen.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- EraGen Again Moving Multiplex Assays Toward Clinic in Wake of Luminex Separation
May 27, 2010 / PCR Insider - Recent Studies Prop Up Multiplex PCR Testing for Respiratory Viruses
May 26, 2010 / PCR Insider - Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
May 19, 2010 / PCR Insider - Luminex Combining EraGen, GenturaDx Techs to Reach HT, Lower-Plex, and LDT Markets
December 13, 2012 / PCR Insider - Luminex Looks to Target Mid- to Low-Volume MDx Labs with GenturaDx Platform
July 12, 2012 / PCR Insider